Healthcare
from24/7 Wall St.
1 day agoMerck Stock Jumps But Reddit Traders Are Getting Cold Feet
Merck's restructuring into oncology and specialty pharma divisions reflects investor concerns about Keytruda's 2028 patent expiration threatening half its revenue, despite management's $70 billion opportunity projection.